Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Glofitamab demonstrated a 39% complete response (CR) rate (95% confidence interval (CI), 32 to 48) among 155 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including a 35% CR rate in a subgroup of 52 patients who had previously received Chimeric Antigen Receptor (CAR) T-cell therapy.
• The median time to achieve a complete response was 42 days (95% CI, 42 to 44), and 78% of those who achieved CR maintained it at 12 months. The 12-month progression-free survival (PFS) rate was 37% (95% CI, 28 to 46).
• No direct comparative effectiveness data with other drugs were provided in the source.
• Cytokine release syndrome (CRS) was the most common adverse event, occurring in 63% of patients, with 4% experiencing CRS of grade 3 or higher. Neurologic events of grade 3 or higher occurred in 3% of patients.
• Adverse events of grade 3 or higher occurred in 62% of patients, and 9% of patients discontinued glofitamab due to adverse events.
• The study focused on patients with relapsed or refractory DLBCL who had received at least two lines of previous therapy. Among the 52 patients who had previously received CAR T-cell therapy, the complete response rate was 35%, slightly lower than the overall response rate of 39%. No specific safety data for this subgroup were provided.